The biomarker technologies market accounted for $21,594 million in 2018, and is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026.
Biomarker is a biological marker, which indicates a substance or a physical event. These indicated substances or events can be measured and the measurements can be further used for the detection of diseases, a physiological change, response to a treatment and a psychological condition. Biomarker technologies are different techniques, which are employed for testing various diseases. These technologies employ the use of different products to measure a biomarker. Reagents and assays are used in various biomarker technologies such as next generation sequencing, polymerase chain reaction, and others. These biomarker technologies are used in various fields of science such as drug discovery, diagnostics, and personalized medicine. Majorly biomarkers are used to detect diseases such as cancer, infectious diseases, autoimmune diseases, neurological disorders, and others.
Rise in prevalence of various diseases such as autoimmune diseases, cancers, and infectious disease boosts the growth of this market. In addition, the rise in research related to drug discovery, increase in healthcare expenditure, and surge in use of personalized medicine are some other factors that contribute toward the growth of this market. The rise in awareness toward the need of early detection of various diseases such as cancers and high growth potential in emerging economies is anticipated to provide lucrative opportunities in the market during the forecast period. However, high initial investment required for biomarker discovery restricts the growth of the biomarker technologies market.
The biomarker technologies market is segmented based on product, technology, application, indication, and region to provide a detailed assessment of the market. Based on product, the market is divided into consumables, and instruments. The consumables segment is further bifurcated into reagents and assays. Based on technology, the market is divided into polymerase chain reaction, next generation sequencing, immunoassays, and others. On the basis of application, the market is classified into drug discovery, diagnostics and personalized medicine. Based on indication, the market is divided into cancer, infectious diseases, autoimmune disorders, cardiovascular disorders, and others. Based on region, the biomarker technologies market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global biomarker technologies market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2018 to 2026 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of biomarker technologies such as polymerase chain reaction, next generation sequencing, immunoassay and others is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Product
o Reagent
By Technology
By Application
By Indication
By Region
o Canada
o Mexico
o France
o UK
o Italy
o Spain
o Rest of Europe
o China
o Japan
o Australia
o South Korea
o Rest of Asia-Pacific
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
Rise in prevalence of various diseases such as autoimmune diseases, cancers, and infectious disease boosts the growth of this market. In addition, the rise in research related to drug discovery, increase in healthcare expenditure, and surge in use of personalized medicine are some other factors that contribute toward the growth of this market. The rise in awareness toward the need of early detection of various diseases such as cancers and high growth potential in emerging economies is anticipated to provide lucrative opportunities in the market during the forecast period. However, high initial investment required for biomarker discovery restricts the growth of the biomarker technologies market.
The biomarker technologies market is segmented based on product, technology, application, indication, and region to provide a detailed assessment of the market. Based on product, the market is divided into consumables, and instruments. The consumables segment is further bifurcated into reagents and assays. Based on technology, the market is divided into polymerase chain reaction, next generation sequencing, immunoassays, and others. On the basis of application, the market is classified into drug discovery, diagnostics and personalized medicine. Based on indication, the market is divided into cancer, infectious diseases, autoimmune disorders, cardiovascular disorders, and others. Based on region, the biomarker technologies market size is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global biomarker technologies market along with the current trends and future estimations to elucidate the imminent investment pockets.
A quantitative analysis from 2018 to 2026 is discussed to enable the stakeholders to capitalize on the prevailing market opportunities.
In-depth analysis of biomarker technologies such as polymerase chain reaction, next generation sequencing, immunoassay and others is carried out in the report.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Product
- Consumables
o Reagent
- Instruments
By Technology
- Polymerase Chain Reaction (PCR)
- Next Generation Sequencing (NGS)
- Immunoassay
- Others
By Application
- Drug Discovery
- Diagnostics
- Personalized Medicine
By Indication
- Cancer
- Infectious Diseases
- Autoimmune Disorders
- Cardiovascular Disorders
- Others
By Region
- North America
o Canada
o Mexico
- Europe
o France
o UK
o Italy
o Spain
o Rest of Europe
- Asia-Pacific
o China
o Japan
o Australia
o South Korea
o Rest of Asia-Pacific
- LAMEA
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- F. Hoffmann-La Roche AG
- Illumina, Inc.
- LI-COR, Inc.
- Merck KGAA
- PERKINELMER INC.
- QIAGEN
- Shimadzu Corporation
- Thermo Fisher Scientific, Inc.
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request)
- Eurofins Scientific
- Enzo Biochem, Inc.
- EKF Diagnostics Holdings plc
- Myriad Genetics, Inc. (Myriad RBM.).
- Becton, Dickinson and Company
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: BIOMARKER TECHNOLOGIES MARKET, BY PRODUCT AND SERVICES
CHAPTER 5: BIOMARKER TECHNOLOGIES MARKET, BY TECHNOLOGY
CHAPTER 6: BIOMARKER TECHNOLOGIES MARKET, BY APPLICATION
CHAPTER 7: BIOMARKER TECHNOLOGIES MARKET, BY INDICATION
CHAPTER 8: BIOMARKER TECHNOLOGIES MARKET, BY REGION
CHAPTER 9: COMPETITIVE LANDSCAPE
CHAPTER 10: COMPANY PROFILES: BIOMARKER TECHNOLOGIES MARKET
Samples
LOADING...
Executive Summary
According to this report titled, 'Biomarker Technologies Market by Product, Technology, Application, and Indication: Global Opportunity Analysis and Industry Forecast, 2019 - 2026,' the biomarker technologies market accounted for $21,594 million in 2018 is expected to reach $58,508 million by 2026, registering a CAGR of 13.2% from 2019 to 2026.Biomarker technologies are techniques that are used to find out biomarkers. These biomarkers are characteristics, genes, or molecules which are used to measure the biological parameters of the body. These biological parameters help in identification of various diseases and can also be helpful in drug discovery. Different technologies, which are used for the identification of biomarkers include next generation sequencing, polymerase chain reactions, immunoassays, and others. These techniques are utilized in various field of science and are mostly used in identification of different disease such as cancers, autoimmune diseases, infectious diseases, and others. Moreover, the use of biomarkers has revolutionized patient treatment, which has become more personalized leading to better treatment outcomes.
The key factors that drive the growth of the global biomarker technologies market are rise in prevalence of various diseases such as cancer, autoimmune diseases, and others. The other factors that contribute toward the growth of the market include surge in research related to drug discovery and increase in healthcare expenditure. However, high initial investments for the discovery of biomarker can hamper the market growth to a certain extent. Whereas, surge in awareness associated with the need of early detection of various diseases such as cancers and high growth potential in emerging economies are anticipated to provide lucrative opportunities in the market during the forecast period.
On the basis of technology, the immunoassay segment was a major revenue contributor in 2018 and is expected to maintain its dominant position throughout the analysis period due to surge in prevalence of various diseases across the globe. For instance, the rise in prevalence of cancer contributes to the growth of biomarker technologies market as biomarkers serve as tools in diagnosis of cancer. Moreover, other diseases such as diabetes type 1, is highly prevalent worldwide. This factor contributes toward the growth of the biomarker technologies market. In addition, infectious diseases such as AIDS, tuberculosis, and others are also diagnosed using biomarkers. Therefore, the factors above mentioned are responsible for the growth of this segment. On the other side, next generation sequencing is expected to be the fastest growing segment during the forecast period as this technique is highly advantageous due to its property of differentiating between closely related tumor cells to provide better understanding of the growth of cancer. Moreover, the rise in research related to cancer worldwide is another factor that boosts the growth of this market.
According to product, the consumables segment accounted for the highest market share in 2018, and is anticipated to maintain this trend during the forecast period, as consumables form an important part of biomarker testing. Instrument segment is the fastest growing segment during the forecast period owing to the technological advancements.
In 2018, North America accounted for the major share of biomarker technologies market size and is expected to continue this trend owing to higher number of R&D activities, presence of skilled technicians, and wide availability of technologically advanced biomarker testing instruments and high prevalence of disease such as cancer, infectious diseases, neurological disorders, autoimmune diseases, and others. On the other side, Asia-Pacific is estimated to register the fastest growth during the forecast period.
Key Findings of the Biomarker Technologies Market:
Consumables occupied two-third share of the market in 2018.
The next generation sequencing segment is anticipated to grow with the highest CAGR throughout the forecast period.
The drug discovery segment accounted for half share of the global biomarker technologies market in 2018.
The cardiovascular disorders segment is anticipated to grow at the highest rate during the analysis period.
The major companies profiled in this report include Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche AG, Illumina, Inc., LI-COR, Inc., Merck KGAA, PerkinElmer Inc., QIAGEN, Shimadzu Corporation, and Thermo Fisher Scientific, Inc.
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
